CODE Production Spółka z Ograniczoną Odpowiedzialnością (KRS 0000727057, NIP 7831776540) is a Polish company, headquartered in Poznań, Wielkopolskie voivodeship. CODE PRODUCTION operates in: Manufacture of pharmaceutical preparations (PKD 21.20.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since April 11, 2018.
Historical suspension of activities
Suspension: March 10, 2021 - resumed: May 28, 2025
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - CODE Production
Identity
- Name
- CODE Production Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 11, 2018
- Registry status as of
- January 28, 2026
- Latest entry
- January 27, 2026
- Founding act
- 05.04.2018 R.
Articles of association history (1)
- April 5, 2018: 05.04.2018 R.
Activities
Main activity
21.20.ZManufacture of pharmaceutical preparations
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. 3 MAJA, 49C, 6, 61-728, POZNAŃ, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.4079, 16.9335approx.
Risk and payment profile - CODE Production
Credibility rating
55.5 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
3
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/8 yrs
Board changes
1
1/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2025
Current: C (56/100)
Trend: stable (+0.5 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2018–2025
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - CODE Production
Founded
April 11, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
POZNAŃ
WIELKOPOLSKIE
Primary PKD
21.20.Z
Manufacture of pharmaceutical preparations
Share capital
5.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
8 years
2018–2025
Registry entries
31
latest: January 27, 2026
Revenue
N/A
2025
Net profit
0 PLN
2025
Assets
5.0 K PLN
2025
Equity
5.0 K PLN
2025
Valuation
4.3 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - CODE Production.
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) - the only Polish manufacturer of biosynthetic human insulin - closed 2025 with revenue of PLN 235.9 m and EBITDA of PLN 53.82 m (margin 18.72%), but a net loss of around PLN -16.4 m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6 m), driven by international expansion (Malaysia ~PLN 100 m a year) and a contract to produce the insulin analogue Glargine. Yifan Pharmaceutical controls 31.65% of capital indirectly.
News
Celon Pharma 2025: record PLN 244 m revenue, but net loss deepens to PLN 79.4 m - the 2026 outlook hinges on Salmex registration in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin/Łomianki) closed 2025 with consolidated revenue of PLN 244.34 m (+17.9% YoY), EBITDA of PLN 21.42 m (+42%) and a deepened net loss of PLN -79.36 m (vs PLN -34.45 m a year earlier). The deeper loss reflects spending on the innovative GLP-1 segment. The generics segment grows (+15.3%) and represents 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of capital and 68.2% of voting rights through Glatton sp. z o.o.
